Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Lithuania

Coordination and Support Action · Running

TWINFLAG Twinning for Promoting Excellence, Ability and Knowledge to develop novel approaches for targeting inflammatory and degenerative age-related joint diseases

Coordinator
Valstybinis Moksliniu Tyrimu Institutas Inovatyvios Medicinos Centras, Lithuania
Runs
1 January 2023 to 30 June 2026
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
4 organisations in 3 countries
Type
Coordination and Support Action
Grant agreement
101079489

What the project is doing

In the project's own words, from its summary on CORDIS.

TWINFLAG is an advanced research consortium consisting of top-class institutions in the field of extracellular vesicles (EVs), flow cytometry and biobanking. The main objective of TWINFLag is to improve capacities of IMC in Lithuania, to implement the excellence in translational research of arthritis treatment and extracellular vesicle (EV)-based biomarker development, innovation and research management. For this purpose, the consortium gathered leading academic institutions in the field of biomedical sciences from Ireland (UCD) and Spain (INIBIC) which will seek to raise the research profile of IMC.

The consortium partners will share their knowledge during organized schools, short term visits and seminars, will implement a small scale research for a personalized therapeutic approach focusing on major research interests of IMC – degenerative and inflammatory arthritis. Currently available tools for the disease-modifying therapy of both rheumatoid and osteo- arthritis are not satisfactory, which is highly associated with the lack of specific and sensitive disease biomarkers.

The need for the application specific disease biomarkers has been emphasized as they increase the success rate of drug development programmes and thereby accelerate the availability of new therapeutics. Partnerships that provide access to tissue banks, data, cell lines, biomarkers, patients and funding are essential for the development of novel therapeutics. Therefore, this three partner consortium identified the demand to develop an innovative joint-research strategy comprising application of novel therapeutics for arthritis, associated with the development of precision biomarkers for monitoring the efficacy of this treatment.

The results of this project will contribute to increased attractiveness of IMC, retention of research talents and mobilization of national and European resources for strategic investments, as well as foster networking and business ideas.

Who is involved

OrganisationCityCountryRole
Valstybinis Moksliniu Tyrimu Institutas Inovatyvios Medicinos CentrasVilniusLithuaniaCoordinator
Fundacion Publica Galega De Investigacion Biomedica InibicA CorunaSpainParticipant
Universidad De VigoVigo PontevedraSpainParticipant
University College Dublin, National University of Ireland, DublinDublinIrelandParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI